# Cannabinoids & Antiepileptics & Neurological Agents: Evidence, Pharmacokinetics & Safety Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-interactions-antiepileptics-neurological-agents-evidence-3/ > **Published:** 2026-10-29T01:11:25-04:00 | **Last Modified / Clinically Audited:** 2026-10-29T01:12:08-04:00 > **Clinical Summary:** Physician review of cannabinoid and antiepileptic drug interactions: CYP450 kinetics, clobazam synergy, serum monitoring, and clinical safety protocols. --- Pharmacology & Safety Series Clinically Audited: October 2026 Table of Contents - [Cannabinoids & Antiepileptics & Neurological Agents: Evidence, Pharmacokinetics & Safety Review](#Cannabinoids_038_Antiepileptics_038_Neurological_Agents_Evidence_Pharmacokinetics_038_Safety_Review)[1. The Primary Pharmacokinetic Mechanism](#1_The_Primary_Pharmacokinetic_Mechanism)[Association between prior obesity and development of diabetes mellitus in dogs and cats: a case-control study: research datasets](#Association_between_prior_obesity_and_development_of_diabetes_mellitus_in_dogs_and_cats_a_case-control_study_research_datasets) - [Managing Interactions Without Therapeutic Compromise](#Managing_Interactions_Without_Therapeutic_Compromise)[Does cannabis or CBD interact with Antiepileptics & Neurological Agents?](#Does_cannabis_or_CBD_interact_with_Antiepileptics_038_Neurological_Agents) - [What monitoring or laboratory surveillance is required when taking cannabinoids alongside Antiepileptics & Neurological Agents?](#What_monitoring_or_laboratory_surveillance_is_required_when_taking_cannabinoids_alongside_Antiepileptics_038_Neurological_Agents) - [Related](#Related) # Cannabinoids & Antiepileptics & Neurological Agents: Evidence, Pharmacokinetics & Safety Review **Author & Reviewer:** [Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with antiepileptics & neurological agents primarily through Potent inhibition of CYP2C19 by CBD, leading to multi-fold elevations in active N-desmethylclobazam metabolites, and potential hepatic transaminase elevation when combined with valproic acid. Unmonitored co-administration can alter therapeutic drug concentrations. Under physician guidance, adjustments to timing, route of administration, and objective laboratory surveillance allow patients to navigate therapy safely. ## 1. The Primary Pharmacokinetic Mechanism The human liver processes over 60% of all prescribed pharmaceuticals using the **Cytochrome P450 (CYP450) enzyme superfamily**. Cannabinoids-most notably cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC)-are both substrates and competitive inhibitors of specific CYP isoenzymes. Enzyme Pathway Dynamics **Mechanism:** Potent inhibition of CYP2C19 by CBD, leading to multi-fold elevations in active N-desmethylclobazam metabolites, and potential hepatic transaminase elevation when combined with valproic acid. **Medications Impacted:** Clobazam (Onfi), Valproate (Depakote), Carbamazepine. Featured Peer-Reviewed Investigation University of Liverpool (2028) ### Association between prior obesity and development of diabetes mellitus in dogs and cats: a case-control study: research datasets **Lead Investigators:** Alex German, We wish to thank Jeremy Laxalde for statistical advice | **Identifier:** Clinical Citation **Study Findings & Abstract:** Data supporting a case-control study on the association of obesity and diabetes in dogs and cats. Study abstract as follows: Background: There is an association between obesity and diabetes mellitus (DM) in cats, but whether a similar association exists in dogs remains controversial. Objectives: To investigate potential associations between prior obesity and DM in dogs and cats. Animals: 9,082 dogs and 3,256 cats with DM from veterinary practices across North America. Methods: Electronic health records were retrospectively filtered for diabetic dogs and cats whose first visit was between 1.5y and 5y and 1y and 7y, respectively, and with ≥2 further visits over ≥4y. Using bootstrap-matching, 3 controls per case were selected, matched for breed, sex, neuter status and age. Final matched control datasets comprised 24,284 dogs and 8,409 cats, with a similar follow up and visit frequency. Body condition score categories (underweight, ideal weight, overweight and obese) were constructed based on bodyweight changes during adulthood. The median body condition (mBC) category was also determined. Statistical analyses comprised odds ratios (OR) with 95% confidence intervals (95%-CI), and logistic regression. Results: In dogs, a positive association existed between mBC and subsequent DM for both the overweight (OR 2.27; 95%-CI 2.14, 2.41; P --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).